Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
| ▸ | CASP6 | P55212 | 2/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7049694 | 0.89 | HSD17B10 (0.50) | HSD17B10NPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL7050333 | 0.88 | PPARG (0.39) | CAPN1CTSBGAAANPEPEPHX1 | |
| SCHEMBL7049822 | 0.87 | PPARG (0.43) | HSD17B10GAAANPEPEPHX2NPC1 | |
| SCHEMBL7049135 | 0.85 | SMN1; SMN2 (0.37) | HSD17B10GAAANPEPEPHX2NPC1 | |
| SCHEMBL7050180 | 0.83 | HSD17B10 (0.43) | HSD17B10CASP1CASP3CASP7CASP6 | |
| SCHEMBL7051089 | 0.83 | SIRT5 (0.38) | HSD17B10GAAEPHX2KDM4ECYP3A4 | |
| SCHEMBL7049709 | 0.82 | PRNP (0.52) | HSD17B10KDM4ENPC1ALDH1A1MAPT | |
| SCHEMBL7051282 | 0.82 | MAPT (0.41) | GAAEPHX1ALDH1A1MAPT | |
| SCHEMBL7052860 | 0.77 | EPHX2 (0.46) | HSD17B10EPHX2NPC1ALDH1A1MEN1 | |
| SCHEMBL7052148 | 0.77 | POLB (0.45) | HSD17B10EPHX2NPC1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| US-6013792-A | INTERSTITIAL COLLAGENASE INHIBITOR; ANTIARTHRITIC AGENTS, ANTIOSTEOPOROSIS AGENTS | SYNTEX (U.S.A.), INC. (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0712403-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| EP-0726903-B1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996023791-A1 | BRIDGED INDOLES AS MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
| EP-0712403-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX INC (US) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995004735-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | HSD17B10 426/4885CAPN1 125/4885CTSB 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.